Short-course amphotericin is cost-effective for cryptococcal meningitis

By Andrew Czyzewski, medwireNews Reporter

medwireNews: The treatment of cryptococcal meningitis (CM) in resource-limited settings is most effective with a short 1-week course of amphotericin induction therapy coupled with high-dose fluconazole for at least 2 weeks, a Ugandan study suggests.

Study co-author David Boulware (University of Minnesota, Minneapolis, USA) and colleagues say their analysis is "generalizable to sub-Saharan African countries" and that switching to this regimen "could save 150,000 lives annually at a cost of US$ 6220 per life saved."

Around 960,000 people each year are infected with CM worldwide (75% in sub-Saharan Africa) and approximately 625,000 (65%) of these people die within 3 months of infection.

The 2011 World Health Organization guidelines recommend induction treatment with a 2-week regimen of intravenous amphotericin B with oral flucytosine (5FC).

However, many stakeholders instead rely on fluconazole monotherapy because it is more accessible, has lower upfront costs, and lacks the lab monitoring requirements of amphotericin treatment - despite having a 25-30% absolute higher mortality.

In the current study, Boulware et al performed a cost-effectiveness analysis of six CM induction regimens each given over a 14-day period: fluconazole monotherapy(800-1200 mg/day); fluconazole (1200 mg/day) plus 5FC (100 mg/kg per day); short-course amphotericin (1 mg/kg per day) for 7 days plus fluconazole (1200 mg per day) for 14 days; amphotericin alone (0.7-1.0 mg/kg per day); amphotericin (0.7-1.0 mg/kg per day) plus fluconazole (800 mg/day); and amphotericin (0.7-1.0 mg/kg per day) plus 5FC (100 mg/kg per day).

Using actual 2012 healthcare costs in Uganda for medications, supplies, and personnel, and average laboratory costs for three African countries, the researchers calculated quality-adjusted life years (QALYs) for each regimen.

The cost of hospital care ranged from US$ 154 (€ 119) for fluconazole monotherapy to US$ 467 (€ 361) for 14 days of amphotericin with 5FC.

Based on 18 studies investigating outcomes for HIV-infected individuals with CM, the estimated mean one-year survival was lowest for fluconazole monotherapy at 40% and highest for short-course amphotericin with fluconazole at 65%.

Meanwhile, the cost-effectiveness ratio ranged from US$ 20 (€ 15) per QALY for short-course amphotericin with fluconazole to US$ 44 (€ 34) per QALY for amphotericin plus 5FC.

Thus, overall, the most favorable treatment appeared to be short-course amphotericin with fluconazole, with an incremental cost-effectiveness ratio of US$ 15 (€ 12) per additional QALY over fluconazole monotherapy.

"If the results of this study hold up in further trials, the use of long-course amphotericin-based treatment-expensive and difficult to sustain in resource-limited settings-could be minimized, and a billion dollars spread over 30 or so years supporting short-course amphotericin-based treatment could buy nearly 5 million lives in sub-Saharan Africa," said Andrew Farlow (University of Oxford, UK) in an accompanying comment.

He added: "By any threshold, this would be highly cost-effective. If amphotericin became more affordable, the cost would be lower still."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post